Recent insider trends for Akers Biosciences, Inc. (NASDAQ:AKER) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on AKER is anything to go by, investors should pay attention.
Institutions own 02.81% of Akers Biosciences, Inc. (AKER)’s shares. The total value of these holdings, in millions, is $0. Among active positions in the latest quarter, 5 holders increased their positions by a total of 38961 shares, 6 holders decreased the positions by a total of 449201 shares, and 6 holders held their positions. This works out to a net decrease in ownership of 410240 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 2 holders initiated new positions by a total of 24319 shares and 2 holders exited their positions by a total of 10172 shares. This nets out to an increase of 14147 shares and is a bullish sign for AKER.
In the last three months, insiders executed a total of 2 trades. 2 of these were buys. Insider ownership increased by a total of 186277 shares, which suggests that AKER’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 2 buys, and ownership increased by a net of 186277 shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Akers Biosciences, Inc. (NASDAQ:AKER)’s short interest is 194100 shares, or 2.88% of the float. This represents a decrease of -63% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Insider data can help an investor form an outlook on a stock, but it’s important to supplement this data with other information such as technical indicators to form a more complete view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that AKER is a sell, which implies that AKER is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Akers Biosciences, Inc. (NASDAQ:AKER) is overvalued.